- Home
- IVP vs ARTL Comparison
IVP vs ARTL Comparison
Compare IVP & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- ARTL
- Stock Information
- Founded
- IVP 2020
- ARTL 2011
- Country
- IVP United States
- ARTL United States
- Employees
- IVP N/A
- ARTL N/A
- Industry
- IVP Diversified Commercial Services
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- ARTL Health Care
- Exchange
- IVP Nasdaq
- ARTL Nasdaq
- Market Cap
- IVP 3.3M
- ARTL 3.1M
- IPO Year
- IVP 2023
- ARTL N/A
- Fundamental
- Price
- IVP $0.78
- ARTL $11.86
- Analyst Decision
- IVP
- ARTL Strong Buy
- Analyst Count
- IVP 0
- ARTL 2
- Target Price
- IVP N/A
- ARTL $25.00
- AVG Volume (30 Days)
- IVP 489.4K
- ARTL 569.9K
- Earning Date
- IVP 08-13-2025
- ARTL 08-12-2025
- Dividend Yield
- IVP N/A
- ARTL N/A
- EPS Growth
- IVP N/A
- ARTL N/A
- EPS
- IVP N/A
- ARTL N/A
- Revenue
- IVP $15,399,751.00
- ARTL N/A
- Revenue This Year
- IVP N/A
- ARTL N/A
- Revenue Next Year
- IVP N/A
- ARTL N/A
- P/E Ratio
- IVP N/A
- ARTL N/A
- Revenue Growth
- IVP N/A
- ARTL N/A
- 52 Week Low
- IVP $0.63
- ARTL $4.92
- 52 Week High
- IVP $255.00
- ARTL $28.60
- Technical
- Relative Strength Index (RSI)
- IVP 34.42
- ARTL 46.07
- Support Level
- IVP $0.71
- ARTL $11.52
- Resistance Level
- IVP $0.78
- ARTL $16.44
- Average True Range (ATR)
- IVP 0.08
- ARTL 2.06
- MACD
- IVP 0.02
- ARTL -0.86
- Stochastic Oscillator
- IVP 38.97
- ARTL 2.76
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.